How did SLDB's operating expenses trend in Q4 2024?

Solid Biosciences Inc. (SLDB) reported a significant increase in operating expenses in Q4 2024, reflecting the company's ongoing investment in research and development and clinical trials. 1. **Total Operating Expenses**: SLDB's total operating expenses for Q4 2024 were $35.2 million. This represents a 52.2% increase from the $23.1 million reported for the same period in 2023. 2. **Quarterly Comparison**: When comparing the nine months ended Q4 2024 with the same period in 2023, the operating expenses increased by 9.6%, totaling $89.8 million versus $82.0 million. 3. **Net Loss Impact**: The increased operating expenses contributed to a higher net loss for the quarter. SLDB reported a net loss of $32.7 million for Q4 2024, a 56.0% increase from the $21.0 million net loss in Q4 2023. 4. **Financial Position**: Despite the financial strain, SLDB's focus on advancing gene therapy candidates for rare diseases is evident. The company's portfolio includes promising assets like SGT-003 for Duchenne muscular dystrophy and SGT-501 for catecholaminergic polymorphic ventricular tachycardia. In summary, SLDB's operating expenses in Q4 2024 were substantial and reflected the company's continued investment in its pipeline of genetic medicines.